Apixaban Dosing for Cancer-Associated Upper Extremity DVT
Continue apixaban 5 mg twice daily for at least 6 months from the initial thrombotic event, then consider dose reduction to 2.5 mg twice daily for extended anticoagulation as long as the cancer remains active. 1, 2
Initial Treatment Phase (First 6 Months)
For your patient with lung cancer and right arm DVT currently on apixaban twice daily, the standard dosing regimen depends on where they are in their treatment course:
- Days 1-7: Apixaban 10 mg orally twice daily 1, 2
- After day 7 through month 6: Apixaban 5 mg orally twice daily 1, 2
The 2024 NCCN guidelines designate apixaban as a Category 1 (preferred) agent for DVT/PE in cancer patients, with the caveat that DOACs are preferred for patients without gastric or gastroesophageal lesions. 1 The 2022 International Clinical Practice Guidelines upgraded apixaban to Grade 1A recommendation based on robust evidence from multiple randomized trials. 3
Extended Anticoagulation (After 6 Months)
Once your patient completes 6 months of full-dose therapy, transition to apixaban 2.5 mg twice daily for extended secondary prophylaxis as long as the cancer remains active. 1, 2, 4
This recommendation is supported by:
API-CAT trial (2025): The highest-quality recent evidence directly addressing this question. In 1,766 patients with active cancer who completed ≥6 months of anticoagulation, reduced-dose apixaban 2.5 mg twice daily was noninferior to full-dose 5 mg twice daily for preventing recurrent VTE (2.1% vs 2.8%, P=0.001 for noninferiority). Critically, the reduced dose resulted in significantly less clinically relevant bleeding (12.1% vs 15.6%, P=0.03) with similar mortality rates. 4
FDA labeling explicitly states: "The recommended dose of ELIQUIS is 2.5 mg taken orally twice daily after at least 6 months of treatment for DVT or PE." 2
Special Considerations for Upper Extremity DVT
While most evidence focuses on lower extremity DVT and PE, emerging data specifically support reduced-dose DOACs for upper extremity DVT:
- A 2023 observational study of 43 patients with secondary upper extremity DVT (including cancer-associated cases) showed zero thromboembolic recurrences during extended treatment with low-dose apixaban 2.5 mg twice daily in patients with persistent risk factors or incomplete recanalization. 5
Duration of Anticoagulation
Continue anticoagulation indefinitely as long as the cancer remains active. 1, 3
- Both NCCN 2024 and the 2022 International Guidelines emphasize that cancer-associated VTE requires extended anticoagulation throughout the period of active malignancy 1, 3
- Reassess the need for continued anticoagulation at regular intervals based on cancer status, bleeding risk, and patient preference 3
Key Caveats and Monitoring
Avoid dose reduction if the patient is taking combined P-gp and strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir). In patients already on 2.5 mg twice daily, avoid these drug combinations entirely. 2
Do not use the 2.5 mg dose reduction criteria for atrial fibrillation (age ≥80, weight ≤60 kg, creatinine ≥1.5 mg/dL) in the VTE setting—these are different indications with different dosing algorithms. 2
Ensure creatinine clearance is ≥30 mL/min before continuing apixaban, as this is required for safe use in cancer-associated VTE. 3